koselugo specialty pharmacy
The most common side effects of Koselugo are: These are not all the possible side effects of Koselugo. This piece provides information for those patients seeking affordability for their TAGRISSO medication. This sheet is available to download as an Adobe PDF. LOUISVILLE, Ky.--(BUSINESS WIRE)--Onco360®, the nation’s largest independent Oncology Pharmacy, has been selected by AstraZeneca to be a specialty pharmacy partner for KOSELUGO™ (selumetinib), a novel oral kinase inhibitor indicated for the treatment of pediatric patients aged two years and above, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. This can be done by the pharmacy or by calling an Access 360 representative. This piece provides a contact list of specialty pharmacy providers and specialty distributors that handle TAGRISSO. “What is neurofibromatosis type 1?”. KOSELUGO™ (selumetinib). Noa Biran, MD: For the most part patients can receive drugs from any specialty pharmacy. Skin rash. Koselugo can cause eye problems that can lead to blindness. These drugs are available only at Panther Rx Specialty Pharmacy. Tag Archives: KOSELUGO. Tell your healthcare provider right away the first time that you get diarrhea during treatment with Koselugo. Brand name drugs are shown in CAPITAL letters. Cart. DOWNLOAD. Koselugo can lower the amount of blood pumped by your heart, which is common and can also be severe. Tell your healthcare provider right away if you get any of the following signs or symptoms: Eye problems. KOSELUGO Affordability Brochure. check back later to download it as an Adobe PDF. But there are not a lot of pharmacies that we personally deal with. “As a specialty pharmacy dedicated to serving patients with cancer and other orphan and rare diseases, we are committed to improving the lives of pediatric patients suffering from neurofibromatosis type 1-associated plexiform neurofibromas.”. Simply bring the coupon below to the pharmacy, and save on Koselugo at CVS, Walgreens, Walmart, Safeway, Albertsons, Rite Aid, Target, Kroger, and many other drug stores! UPPERCASE Brand-name medicine ; lowercase italics : Generic medicine (Quantity Limits) Drug has quantity limits on some plans. Each specialty pharmacy drug below is categorized according to its most commonly recognized therapeutic indication or treatment class. Key . Access 360 provides: • Assistance with understanding patient insurance coverage and pharmacy options • Prior authorization support • Claims and appeal process support • Eligibility requirements and enrollment assistance for specialty Patient Savings Programs • Referrals to patient assistance programs Skin rashes are common with Koselugo and can also be severe. 502.630.7412 LOUISVILLE, Ky.--(BUSINESS WIRE)-- Onco360 ®, the nation’s largest independent Oncology Pharmacy, has been selected by AstraZeneca to be a specialty pharmacy partner for KOSELUGO™ (selumetinib), a novel oral kinase inhibitor indicated for the treatment of pediatric patients aged two years and above, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. No products in the cart. Get Selumetinib Medication Sheet. Especially tell your healthcare provider if you are taking aspirin, blood thinners, or other medicines to treat blood clots. KOSELUGO is manufactured by AstraZeneca, a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, and was approved by the U.S. Food and Drug Administration (FDA) on April 10, 2020, to treat pediatric patients (aged two years and older) with NF1 and symptomatic, inoperable plexiform neurofibromas. This piece provides information for those patients seeking affordability for their KOSELUGO medication. This type of pharmacy takes a one-to-one personalized … Pharmacy Advantage Specialty Drug List To assure safe and quality care, specialty drugs require a prior authorization and must be obtained from the HAP Specialty Pharmacy: Pharmacy Advantage (800) 456‐2112. Selumetinib (Koselugo™) is used for pediatric patients (2 years of age or older) to treat neurofibromatosis type (NF1) with plexiform neurofibromas that cannot be removed by surgery. Additionally, plexiform neurofibromas commonly recur following optimal surgical resection, thus representing a significant area of unmet medical need1,2. Page 1 … 0. Regardless of how the drug is classified, prior authorization may be required … Before taking Koselugo, tell your healthcare provider about all of your medical conditions, including if you: Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. The generic drugs are shown in lowercase type. (Step Therapy) Drug has step therapy requirements on some plans. This sheet is coming soon. Your healthcare provider may give you medicine to help control your diarrhea and may tell you to drink more fluids. These coupons are free and can be used to save up to 80% on all medications. Koselugo is a prescription medicine that is used to treat children 2 years of age and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas that cannot be completely removed by surgery. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. March 13, 2020 A specialty pharmacy will stock many of the drugs that are not usually stocked in your community or retail pharmacy. Shop. TAGRISSO Affordability Brochure. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-children-debilitating-and-disfiguring-rare-disease. Tell your healthcare provider right away if you get any of the following signs or symptoms: Your healthcare provider may change your dose, temporarily stop, or permanently ask you to stop taking Koselugo if you have any of these side effects. Some medications on this list may require dispensing by another HAP selected specialty pharmacy. Koselugo can harm your unborn baby, Females who could become pregnant and males with female partners who could become pregnant should use effective birth control (contraception) during treatment with Koselugo and for 1 week after your last dose, Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment, are breastfeeding or plan to breastfeed. “The approval of KOSELUGO represents a new treatment strategy for children suffering from the debilitating effects of plexiform neurofibromas arising from NF1,” said Paul Jardina, President and CEO, Onco360. Available at: https://www.chop.edu/conditions-diseases/neurofibromatosis-type-1. Onco360 offers a single sourcing solution for the complex, multi-drug therapy regimens that make up today’s cutting-edge cancer treatment protocols. It is not known if Koselugo is safe and effective in children under 2 years of age. Vice President, Communications and PR Your healthcare provider will do tests before and during treatment with Koselugo to check how well your heart is working. 1. KOSELUGO™ (selumetinib) is the FIRST and ONLY FDA-approved prescription medicine that is used to treat children 2 years of age and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas that cannot be completely removed by surgery. Some drugs can be used for indications other than those that are listed below. FASENRA Sample Letter of Medical Necessity. Koselugo may cause serious side effects, including: Heart problems. Diarrhea is common with Koselugo and can also be severe. Your healthcare provider will check your vision before and during treatment with Koselugo. or requires the use of a specialty pharmacy. Checklists designed to be used as a reference during the prior authorization (PA) and denial/appeal processes for FASENRA. Plexiform neurofibromas can cause the following symptoms dependent upon location: disfigurement, pain, motor dysfunction, visual loss, airway compromise, weakness, bowel dysfunction, bladder dysfunction, and mobility issues. (National Precertiication List) Prior authorization is required for all plans. … WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved the kinase inhibitor KOSELUGO™ (selumetinib) for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 (NF1) who … This sheet provides the contact information of authorized Specialty Pharmacy Providers and Specialty Distributors, from which FASENRA can be obtained. It is not known if Koselugo is safe and effective in children under 2 years of age. Our Medication Sheet. Unfortunately, many patients are not surgical candidates due to the location or volume of these tumors. LOUISVILLE, Ky.--(BUSINESS WIRE)--Onco360 ®, the nation’s largest independent Oncology Officials with the FDA have approved the kinase inhibitor selumetinib (Koselugo, AstraZeneca and Merck & Co) for the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN), the companies announced Monday. Your healthcare provider should do a blood test to check your muscle enzyme levels before you start taking Koselugo and during treatment. No products in the cart. Accessed April 2020. DOWNLOAD. Accessed April 2020. Muscle problems are common with Koselugo and can also be severe. Treatment with Koselugo may increase the level of a muscle enzyme in your blood, which may be a sign of muscle damage. For full prescribing information, visit KOSELUGO.com. NF1 is a rare, progressive genetic disorder, occurring in approximately one in every 3000 live births, which can affect multiple organ systems and is characterized by changes in skin pigmentation, neurologic impairment, skeletal impairment, development of benign tumors, and development of malignant tumors. FASENRA Prior Authorization and Appeal Checklist . 2. Our specialty pharmacy team consists of pharmacists, pharmacy technicians and nurses that are dedicated to help prepare you to start and to support continuation on these high cost, chronic specialty medications. This piece provides a contact list of specialty pharmacy providers and specialty distributors that handle KOSELUGO. communication@brightspringhealth.com, https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-children-debilitating-and-disfiguring-rare-disease, https://www.chop.edu/conditions-diseases/neurofibromatosis-type-1. “FDA Approves First Therapy for Children with Debilitating and Disfiguring Rare Disease”. The pharmacy will use the Co-pay Savings Program to cover the balance, up to the program maximum. * ONCO360 - HAS BEEN SELECTED BY ASTRAZENECA TO BE A SPECIALTY PHARMACY PARTNER FOR KOSELUGO Source text for Eikon: Further company coverage: It is not known if Koselugo passes into your, Do not breastfeed during treatment with Koselugo and for 1 week after your last dose, Talk to your healthcare provider about the best way to feed your baby during this time, rash that covers a large area of your body, feeling of tiredness, weakness, or lacking energy, Koselugo and AstraZeneca Access 360 are trademarks of the AstraZeneca group. Onco360® has been selected by AstraZeneca to be a specialty pharmacy partner for KOSELUGO™ (selumetinib), a novel oral kinase inhibitor indicated for the treatment of pediatric patients aged two years and above, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. Onco360 is Your Single Source For All Of Your Oncology & Hematology Pharmacy Needs. For personalized Koselugo support, call 1-844-ASK-A360 (1-844-275-2360)1-844-ASK-A360 (1-844-275-2360) or visit www.MyAccess360.com. Leigh White DOWNLOAD. NOTE: the pricing for a Koselugo prescription is often expensive and you may need to fill it using a specialty pharmacy. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support